Cramer's 'Mad Money' Recap: Fill 'Er Up With ConocoPhillips

Savient Savvy

Cramer welcomed Christopher Clement, Savient Pharmaceuticals' (SVNT Quote) president and CEO, to the show and asked him about his company's gout drug.

The drug's name is Puricase, and it is in phase III of its clinical studies. This will be the last set of studies before Savient submits it for Food and Drug Administration approval, Clement said.

Savient plans to file for FDA approval in early 2008 and launch the drug in early 2009, Clement continued. With Puricase, Savient has the opportunity to help patients with gout flare. While initially Puricase will be for the treatment-failure patient population, later on, said Clement, Savient plans to extend it to a larger patient population.

Cramer advised sticking with Savient and buying the stock on any weakness.

To view Cramer's interview with Christopher Clement, please click here.

Sears Update

On a closing note, Cramer addressed Sears Holdings' (SHLD Quote) recent 17% decline.

"The company has to start making some sales and selling some of its real estate," he said.

The current situation is such that Cramer believes people should hold Sears for 18 months. Cramer said that while he is disappointed in the stock, which he owns for his charitable trust, he is not selling it now.